Scarica l'app Stockscreener
4.3302
2.27%
-0.0798
Precedente Chiudi:
$4.41
Aprire:
$4.41
Volume 24 ore:
20,065
Relative Volume:
0.07
Capitalizzazione di mercato:
$40.62M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+3.11%
1M Prestazione:
+6.95%
6M Prestazione:
-82.49%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.285
$4.42
Intervallo di 1 settimana:
$4.13
$4.71
Portata 52W:
$3.74
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Nome
Tvardi Therapeutics Inc
Settore
Industria
Telefono
(713) 489-8654
Indirizzo
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Confronta TVRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.3302 | 41.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.26 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.51 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.87 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.56 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.40 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-10-13 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Iniziato | Raymond James | Outperform |
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
Mostra tutto
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
What analysts say about Tvardi Therapeutics Inc stockCash Flow Trends & Affordable Portfolio Growth - earlytimes.in
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - PR Newswire
Tvardi Therapeutics (TVRD) Price Target Decreased by 24.64% to 15.15 - MSN
How Low Can Tvardi Therapeutics Stock Really Go? - Trefis
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga
Will Tvardi Therapeutics Inc. (69C) stock outperform value peersJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - Newser
Can Tvardi Therapeutics Inc. stock sustain institutional interestTrade Exit Summary & Detailed Earnings Play Alerts - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - Barchart.com
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Tvardi Therapeutics - Menafn.com
Is Tvardi Therapeutics Inc. (69C) stock trading at attractive multiplesChart Signals & Fast Exit and Entry Trade Guides - Newser
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
With Tvardi Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Will Tvardi Therapeutics Inc. (69C) stock see insider accumulationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
How big funds are accumulating Tvardi Therapeutics Inc. (69C) stockJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - Newser
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics - The National Law Review
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GlobeNewswire
Why retail investors favor Tvardi Therapeutics Inc. stockWeekly Trade Report & Capital Protection Trading Alerts - moha.gov.vn
Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen - Defense World
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario - TipRanks
Will Tvardi Therapeutics Inc. (69C) stock enhance shareholder value2025 Momentum Check & Smart Money Movement Tracker - newser.com
Can Tvardi Therapeutics Stock Recover If Markets Fall? - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
How Tvardi Therapeutics Inc. (69C) stock reacts to stronger dollarPortfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Is Tvardi Therapeutics Inc. stock ready for a breakoutPortfolio Performance Summary & Capital Protection Trading Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Weekly Recap & Weekly Breakout Stock Alerts - newser.com
Can Tvardi Therapeutics Inc. (69C) stock expand revenue streamsJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
What valuation ratios show for Tvardi Therapeutics Inc. (69C) stockJuly 2025 Big Picture & Trade Opportunity Analysis - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tvardi Therapeutics, Inc. (TVRD) And Encourages Shareholders to Connect - ACCESS Newswire
Can Tvardi Therapeutics Inc. (69C) stock deliver double digit returnsRisk Management & Weekly Chart Analysis and Trade Guides - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
How Tvardi Therapeutics Inc. stock reacts to global recession fearsEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Tvardi Therapeutics Inc Azioni (TVRD) Dati Finanziari
Non sono disponibili dati finanziari per Tvardi Therapeutics Inc (TVRD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):